Bristol Expands Fibrosis Pipeline With Galecto Buy Option
This article was originally published in Start Up
Three-year-old Galecto Biotech on November 3 secured funding and validation from Bristol-Myers Squibb Co. in an option-to-buy deal that could be worth up to $444 million. Galecto’s lead asset, an inhaled inhibitor of galectin-3 in development for idiopathic pulmonary fibrosis, has only just entered human testing. But IPF – and fibrosis more broadly – has become something of a hot-spot.